Current Report Filing (8-k)
March 13 2018 - 7:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 12, 2018
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-33038
|
|
84-1475642
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
One First Avenue, Parris Building 34, Navy Yard Plaza
Boston, Massachusetts
|
|
02129
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(617)
259-1970
(Registrants telephone number, including area code)
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the
Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR 240.14a-12).
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b)).
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c)).
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule
12b-2
of the Exchange Act (17 CFR
240.12b-2).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b) On March 12, 2018, Dr. Michael Weiser resigned from the board of directors, or the Board, of Ziopharm Oncology, Inc., or
the Company, including all committees thereof, effective immediately.
Effective March 12, 2018, the Board appointed James Cannon to
serve on the Boards compensation committee. Following such appointment, the members of the compensation committee are Scott Tarriff, who will serve as the committees chairman, Dr. Murray Brennan and James Cannon.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZIOPHARM ONCOLOGY, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Kevin G. Lafond
|
Date: March 13, 2018
|
|
|
|
Name:
|
|
Kevin G. Lafond
|
|
|
|
|
Title:
|
|
Sr. Vice President Finance, Chief Accounting Officer and Treasurer
|
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Sep 2023 to Sep 2024